PBYIPuma Biotechnology, Inc.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +41% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How PBYI is trading
Puma Biotechnology, Inc. is +111% over the past year while the S&P 500 is +16%: 95 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +41%
vs 200-day average · a clear uptrend
- RSI (14)
- 67
RSI (14) · neutral
- Below its 52-week high
- 2.3%
Below its 52-week high
Details›
- Last close2026-10-23
- $11.03
- 1 monthS&P 500 −0.94%
- +12%
- 1 yearS&P 500 +16%
- +111%
- 5 yearsS&P 500 +86%
- +82%
- vs 50-day average$9.66
- +14%
- 52-week high
- $11.28
- 52-week low
- $4.73
- Annualised volatility
- 67%
| Year | Return |
|---|---|
| 2026 (year to date) | +85% |
| 2025 | +95% |
| 2024 | −30% |
| 2023 | +2.4% |
| 2022 | +39% |
| 2021 | −70% |
| 2020 | +17% |
| 2019 | −57% |
| 2018 | −79% |
| 2017 | +222% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +0.92% |
| Feb | 10 | 4 of 10 | +6.0% |
| Mar | 10 | 5 of 10 | +0.63% |
| Apr | 10 | 5 of 10 | −0.46% |
| May | 10 | 5 of 10 | +0.79% |
| Jun | 10 | 7 of 10 | +5.6% |
| Jul | 11 | 5 of 11 | +1.7% |
| Aug | 11 | 6 of 11 | +5.2% |
| Sep | 11 | 7 of 11 | +1.4% |
| Oct | 11 | 3 of 11 | −12% |
| Nov | 10 | 6 of 10 | +18% |
| Dec | 10 | 2 of 10 | −5.4% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.